AlphAIAlphAI — Financial news for AI agents
fool.com.au$RMD

Would I buy ResMed shares after today's results?

ResMed (ASX: RMD) shares rose 2% to $36.15 after reporting a 6% revenue increase to $1.41B in Q1 FY27. Adjusted EPS grew 14%, and margins improved. Management maintained FY27 guidance. The company trades at a forward P/E of 21.3x for FY27, seen as reasonable for its market position and growth prospects.

Original reporting
fool.com.au
Published Oct 30, 2026, 12:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 3:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Would I buy ResMed shares after today's results? — source image
Source · fool.com.au
Decision brief

The 30-second read

$RMDBullishMed
01

Why it matters

Earnings beat and margin expansion suggest continued growth, supporting a bullish stance.

02

Market read

The earnings release provides fresh data that could influence short‑term trading decisions on ResMed.

03

What to watch

Potential headwinds from regulatory changes in sleep‑apnoea device approvals.

Relevance 8/10Novelty 7/10Timing: pre‑market today

Background

ResMed is a global leader in sleep and breathing health devices, listed on the ASX and ADR in the US.

Company-level read

Ticker impact

$RMDBullishHigh confidence
Context

ResMed reported Q1 FY27 results with 6% revenue growth and 14% EPS increase, driving a 2% share rise.

Expected impact

likely upward pressure as investors price in earnings beat and unchanged guidance

Evidence & confidence

Revenue and EPS both exceeded expectations; margin improvement adds credibility to guidance.

Market effects

Sector

Sleep‑technology and medical device sector may see modest rally on strong earnings.

Regional

Australian market may benefit from ResMed's share rise.

Global

Limited to investors focused on health‑tech and ADR exposure.

Counterpoint

What could challenge this read

If guidance remains unchanged, the stock may be overvalued at current multiples.

Key entities

  • company
    ResMed Inc

    Sleep‑technology manufacturer reporting FY27 Q1 results.

Read at source← All news

StoryResMed posts Q1 FY27 beat with $1.4 B revenue, $2.91 EPS and $1 B returned to shareholders

Also covered by

4 outlets

Related articles

$RMDMedAI 8/10

What Sent ResMed Stock Lower?

ResMed (RMD) shares dropped 9.1% on October 30, 2026, following its fiscal Q1 2027 earnings release. The company beat earnings and revenue estimates, with EPS of $2.91 and revenue of $1.41B. Despite 14% higher EPS YoY, revenue growth slowed to 5.9%. Peers also fell, with Stryker (SYK) down 6.4% after missing estimates. The broader market declined due to AI sector selloff. ResMed's stock is down 8.4% over the past year.

finance.yahoo.com
$RMDMed

ResMed (RMD) Q1 2027 Earnings Call Transcript

ResMed (RMD) reported Q1 2027 earnings, highlighting innovation in sleep health products, including new bilevel devices and fabric masks. The company saw a 6% increase in therapy adherence with fabric masks and 4.3% with AI-driven Smart Comfort. ResMed also improved gross margins and expanded U.S. manufacturing. The myAir app, with 13M+ downloads, enhances patient engagement and compliance.

finance.yahoo.com
$RMDMedAI 8/10

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed (RMD) reported Q1 residential care software revenue declined 7% but increased 5% on a constant-currency basis. The company launched new devices and digital tools, with management highlighting growth in patient engagement. Non-GAAP gross margin rose to 62.5%. ResMed maintained its fiscal 2027 guidance, expecting 5-7% core revenue growth and EPS of $12-$12.25. The company is expanding U.S. manufacturing and discontinuing Astral ventilators.

finance.yahoo.com
$RMDHighAI 8/10

ResMed 3Q 2026: Revenue $1.41B, EPS $2.92— 10-Q Summary

ResMed reported 3Q 2026 revenue of $1.41B, up 5.9% YoY, with net income rising 20% to $418.41M and EPS increasing 23.2% to $2.92. Sleep and Breathing Health revenue grew 8%, while Residential software revenue declined 7% post-MatrixCare sale. The company completed the MatrixCare divestiture and expects input-cost inflation to persist through fiscal 2027.

tradingview.com